Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases. The drugmaker ...

SAN RAFAEL, Calif., and PRINCETON, N.J., Dec. 19, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Amicus Therapeutics (Nasdaq: FOLD) announced today that BioMarin has entered into ...

BioMarin Pharmaceutical (BMRN) has agreed to acquire rare disease drug developer Amicus Therapeutics (FOLD) in an all-cash transaction worth nearly $4.8B, the companies announced on Friday. The deal, ...

BioMarin’s $4.8 billion all-cash acquisition of Amicus Therapeutics significantly expands its rare disease portfolio with established Fabry and Pompe franchises, adds late-stage pipeline upside, and ...

This blog will explore the importance, features, benefits, challenges, and future trends associated with pharmacy delivery software. Whether you’re a pharmacy owner, healthcare provider ...

Amicus Brain Innovations has launched an AI-based application, known as Amicus Insightful Navigation to Enrich Relationships, Amplify Connections, and Togetherness (INTERACT), to address ...

A and South Walton dog owners can access board and train, in-home lessons, and behavior programs across Santa Rosa Beach, Destin, and nearby communities. SANTA ROSA, FL, UNITED STATES, January 5, 2026 ...

ISN, the global leader in contractor and supplier information management services, announced Mondi Group, a sustainable packaging and paper provider, expanded its use of ISNetworld to include its ...

This month, I’ll share some of the free software I use to understand how TV signals make it from the transmitter to the ...

08/01/2024 Motion to extend the time to file a response from August 14, 2024 to October 14, 2024, submitted to The Clerk. 08/02/2024 Motion to extend the time to file a response is granted and the ...

The Navy completed a demonstration of its manned-unmanned teaming capabilities to further the development of its ...

BioMarin Pharmaceutical has agreed to buy rare disease biotech Amicus Therapeutics, adding three approved or late-stage lysosomal storage disorder therapies to its portfolio. Under the terms of the ...